Adenovirus-mediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells

Cancer

Volumn 86, Issue 10, 1999, Pages 2021-2033

  Dong, Van Bin ^a   Yang, Hai Liang ^a   Elliott, Mary Jane ^a   Liu, Ta Jen ^b   Stilwell, Ariel ^a   Atienza Jr , Cesar ^a   McMasters, Kelly M ^a  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Adenovirus; Apoptosis; Cell cycle; E2F 1; Gene therapy; Melanoma; P53

Indexed keywords

TRANSCRIPTION FACTOR E2F;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; GENE TRANSFER; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL;

ADENOVIRUS E2 PROTEINS; APOPTOSIS; CELL CYCLE; CELL DIVISION; DOWN-REGULATION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MELANOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0344287260     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991115)86:10<2021::AID-CNCR20>3.0.CO;2-1     Document Type: Article

References (69)

1. Buzaid AC, Bedikian A, Houghton AN. Systemic chemotherapy and biochemotherapy. In: Balch CM, Houghton AN, Sober AJ, Soong S-J, editors. Cutaneous melanoma. St. Louis: Quality Medical Publishing, Inc., 1998:405-418.
2. Liu T-J, El-Naggar AK, Mc Donnell TJ, Steck KD, Wang M, Taylor DL, et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of head and neck. Cancer Res 1995;55:3117-22.
3. Clayman GL, El-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995;55:1-6.
4. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990;249:912-5.
5. Craig C, Kim M, Ohri E, Wersto R, Katayose D, Li ZW, et al. Effects of adenovirus-mediated p16 INK4A expression on cell cycle arrest are determined by endogenous p16 and RB status in human cancer cell. Oncogene 1997;16:265-72.
6. Zhang WW, Fujiwara T, Grimm EA, Roth JA. Advances in cancer gene therapy. Adv Pharmacol 1995;32:289-341.
7. Pardoll D. Immunotherapy with cytokine gene transduced tumor cells: the next wave in gene therapy for cancer. Curr Opin Oncol 1992;4:1124-9.
8. Vile RG, Hart IR. Use of tissue-specific expression of herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intra tumoral injection of DNA. Cancer Res 1993;53:3860-4.
9. Oldfield EH, Ram Z, Culver KW, Blaese RM, Devroom HL, Anderson WF. Gene therapy for treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993;4: 39-69.
10. Hunania EG, Deisseroth AB. Serial transplantation shows that early hematopoietic precursor cells are transducted by MDR-I retroviral vector in a mouse gene therapy model 1. Cancer Gene Ther 1994;1:21-5.
11. Gottesman MM, Germann UA, Aksentijevich I, Sugimoto Y, Cardarelli CO, Pastan I. Gene transfer of drug resistance genes, Implications for cancer therapy. Ann NY Acad Sci 1994;716:126-38.
12. Krek W, Xu G, Livingston DM. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of a S phase checkpoint. Cell 1995;83:1149-58.
13. Shan B, Lee WH. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol Cell Biol 1994;14: 8166-73.
14. Karen L, John AC. Cell cycle and apoptosis: common pathways to life and death. J Cell Biochem 1995;58:175-80.
15. Kasten MM, Giordano A. pRb and CDKs in apoptosis and the cell cycle. Cell Death Diff 1998;5:132-40.
16. Hiebert SW, Bker M, Azizkham J, Nevins JR. Role of E2F transcription factor in E1A-mediated transactivation of cellular genes. J Viral 1991;65:3547-52.
17. Nevins JR. E2F: a link between the RB tumor suppressor protein and viral oncoproteins. Science 1992;258:424-9.
18. Girling R, Bandara LR, Ormondroyd E, Lam EW, Kotecha S, Mohun T and LaThangue NB. A new component of transcription factor DRTF1/E2F. Nature 1993;362:83-7.
19. Helin K, Wu C-L, Fattaey AR, Lees JA, Dynlacht BD, Ngwu C, et al. Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative transactivation. Genes Dev 1993;7:1850-61.
20. Shan B, Zhu X, Chen P-L, Durfee T, Yang Y, Sharp D, et al. Molecular genes encoding retinoblastoma-associated proteins: identification of a gene with properties of the transcription factor E2F. Mol Cell Biol 1992;12:5620-31.
21. Slansky JE, Li Y, Kaelin WG, Farnham PJ. A protein synthesis-dependent increase in E2F-1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Mol Cell Biol 1993;13:1610-8.
22. Krek WD, Livington DM, Shirodkar S. Binding to DNA and the retinoblastoma gene product family members. Science 1993;262:1557-60.
23. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
24. Bagchi S, Weinmann R, Raychaudhuri P. The retinoblastoma protein copurifies with E2F-1, an E1A-regulated inhibitor of the transcription factor E2F. Cell 1992;65:1053-61.
25. Qin XQ, Livingston DM, Kaelin WG Jr., Adams PD. Deregulated transcription factor E2F-1 expression leads to S phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 1994;91:10918-22.
26. Kowalik TF, DeGregori J, Schwarz JK, Nevins JR. E2F-1 over-expression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol 1995;69:2491-500.
27. Hsieh JK, Fredersdorf S, Kouzarides T, Martin K, Lu X. E2F1-induced apoptosis requires DNA binding but not transacti-vation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev 1997;11:1840-52.
28. Phillips AC, Bates S, Ryan KM, Helin K, Vousden KH. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev 1997;11:1853-63.
29. Hunt KK, Deng J, Liu T-J, Wilson-Heiner M, Swisher SG, Clayman G, et al. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res 1997;57:4722-66.
30. Fueyo J, Comez-Manzano C, Yung WKA, Liu TJ, Alemany R, Mcdonnell TJ, et al. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nature Med 1998;4:685-90.
31. Schrump DS, Chen GA, Consuli U, Jin X, Roth JA. Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16INK4. Cancer Gene Ther 1996;3:357-64.
32. Prabhu NS, Blagosklonny MV, Zeng YX, Wu GS, Waldman T, El-Deiry WS. Truncated p21-adenovirus bypass of p53 resistance in the therapy of human cancer [meeting abstract]. Proc Annu Meet Am Assoc Cancer Res 1996;37:A2360.
33. French BA, Mazur W, Ali NM, Geske RS, Finnigan JP, Rodgers GP, et al. Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis. Circulation 1994;90:2402-13.
34. Graham FL, Prevec L Manipulation of adenovirus vectors. In: Murray EJ, editor. Methods in molecular biology, vol 7: gene transfer and expression protocols. Clifton, NJ: The Humana Press Inc.,1991:109-28.
35. Adams DO, Edelson PH, Korren MS, editors. In: Methods for studying mononuclear phagocytes: histochemical stains for macrophages in cell smears and tissue sections: β-galactosidase, acid phosphatase, nonspecific esterase, succinate dehydrogenase, and cytochrome oxidase. New York: Academic Press, 1981:375-96.
36. Lock RB, Galperina OV, Feldhoff RC, Rhodes LJ. Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in HeIa cells. Cancer Res 1994;54:4933-9.
37. He J, Whitacre CM, Xue LY, Berger NA, Oleinick NL. Protease activation and cleavage of poly(ADP-ribose) polymerase: an integral part of apoptosis in response to photodynamic treatment. Cancer Res 1998;58:940-6.
38. Gavriell Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;3:493-501.
39. Schwartzman RA, Cidlowski JA. Apoptosis: the biochemistry and molecular biology of programmed cell death. Endocrine Rev 1993;14:133-51.
40. Evan GI, Brown L, Whyte M, Harrington E. Review: apoptosis and the cell cycle. Curr Opin Cell Biol 1995;7:825-34.
41. Xu G, Livingston DM, Krek W. Multiple members of the E2F transcription family are the products of oncogenes. Proc Natl Acad Sci USA 1995;92:1357-61.
42. Johnson DG, Schwartz JK, Cress WD, Nevins JR. Expression of transcription factor E2F-1 induces quiescent cells to enter S phase. Nature 1993;365:349-52.
43. Singh P, Wong SH, Hong W. Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J 1994;13:3329-38.
44. Field SJ, Tsai F-Y, Kou F, Zubiaga AM, Kaelin WG-J, Livingston DM, et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996;85:549-61.
45. Nasmyth K. Viewpoint: putting the cell cycle in order. Science 1996;274:1643-5.
46. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996;274:1664-71.
47. Jones TL, LaFrenz D. Quantitative determination of the induction of apoptosis in murine B cell line using flow cytometric bivariate cell cycle analysis. Cell Immunol 1992;142: 348-60.
48. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821-8.
49. Arellano M, Moreno S. Review: regulation of CDK/cyclin complexes during the cell cycle. Int J Biochem Cell Biol 1997;29:559-73.
50. Yonish-Rouach E, Grunwald D, Wilder S, Kimchi A, May E, Lawrence J-J, et al. p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol 1993;13:1415-23.
51. Wu XW, Levine AJ. P53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 1994;91:3602-6.
52. Hiebert SW, Packham G, Strom DK, Haffner R, Oren M, Zambetti G, et al. E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol Cell Biol 1995;15: 6864-74.
53. Holmberg C, Heiin K, Sehested M, Karlstrom O. E2F-1-induced p53-independent apoptosis in transgenic mice. Oncogene 1998;17:143-56.
54. Volkenandt M, Schlegel U, Nanus DM, Albino AP. Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell Res 1991;4:35-40.
55. Kroumpouzos G, Eberle J, Garbe C, Orfanos C. p53 mutation and c-fos overexpression are associated with detection of the antigen VLA-2 in human melanoma cell lines. Pigment Cell Res 1994;7:348-53.
56. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
57. Gil-Gomez G, Berns A, Brady HJ. A link between cell cycle and cell death: Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis. EMBO J 1998;17:7209-18.
58. Zhou P, Qian L, Biezvcvad CK, Noelle R, Binder M, Levy NB, et al. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 1998;92:3226-39.
59. Chao DT, Korsmeyer SJ. Bcl-2 family: regulators of cell death. Annu Rev Immunol 1998;16:395-419.
60. Knudson CM, Korsmeyer SJ. Bcl-2 and Bax function independently to regulate cell death. Nat Genet 1997;16:358-63.
61. Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH, Thompson CB, et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sd USA 1995; 92:7834-8.
62. Clem RJ, Cheng EH, Karp CL, Kirsch DG, Ueno K, Takahashi A, et al. Modulation of cell death by Bcl-XL through caspase interaction. Proc Natl Acad Sd USA 1998;95:554-9.
63. van den Oord JJ, Vandeghinste N, De Ley M, De Wolf-Peeters C. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994;145:294-300.
64. Saenz-Santamaria MC, Reed JA, McNutt NS, Shea CR. Immunohistochemical expression of Bcl-2 in melanomas and intradermal nevi. J Cutan Pathol 1994;21:393-7.
65. Tron VA, Krajewski S, Hein-Parker H, Li G, Ho VC, Reed JC. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am J Pathol 1995;146:643-50.
66. Ramsay JA, From L, Kahn HJ. Bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol 1995; 8:150-4.
67. Mooy CM, Luyten GP, de John PT, Luider TM, Stijnen T, van de Jam F, et al. Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Am J Pathol 1995;147:1087-104.
68. Wood DE, Newcomb EW. Caspase-dependent activation of calpain during drug-induced apoptosis. J Biol Chem 1999; 274:8309-15.
69. Wood DE, Thomas A, Devi LA, Berman Y, Beavis RC, Reed JC, Newcomb EW. Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene 1998; 17:1069-78.